Description Results NMA

All cause death 1.04 [0.80; 1.33]

severe bleeding 1.01 [0.54; 1.90]

Serious infection 0.90 [0.65; 1.25]

All cause death 0.42 [0.18; 1.01]

All cause death 0.82 [0.49; 1.40]

pexelizumab given as a 2-mg/kg intravenous bolus prior to PCI followed by 0.05-mg/kg per hour infusion over the subsequent 24 hours (n=2860)

vs.

placebo (n=2885)

double blind

Parallel groups

Sample size: 2860/2885

Primary endpoint: all cause mortality

FU duration: 30 days

pexelizumab 2.0-mg/kg bolus and 0.05-mg/kg per h infusion for 20 hours (n=328)

vs.

placebo (n=315)

3rd arm with pexelizumab 2.0-mg/kg bolus

double blind

Sample size: 328/315

Primary endpoint: creatine kinase-MB area under the curve

FU duration:

pexelizumab 2.0-mg/kg bolus plus 0.05 mg/kg per h for 20 hours (n=315)

vs.

placebo (n=316)

3rd arm with pexelizumab 2.0-mg/kg bolus

double blind

Sample size: 315/316

Primary endpoint:

FU duration:

All cause death 1.04 [0.80; 1.33]

severe bleeding 1.01 [0.54; 1.90]

Serious infection 0.90 [0.65; 1.25]

pexelizumab given as a 2-mg/kg intravenous bolus prior to PCI followed by 0.05-mg/kg per hour infusion over the subsequent 24 hours (n=2860)

vs.

placebo (n=2885)

double blind

Parallel groups

Sample size: 2860/2885

Primary endpoint: all cause mortality

FU duration: 30 days